Baotou Dongbao Bio-Tech Co Ltd Net Assets
Baotou Dongbao Bio-Tech Co Ltd net assets. Based on the latest financial reports, Baotou Dongbao Bio-Tech Co Ltd (300239) has net assets worth CN¥1.74 Billion CNY (≈ $255.04 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.57 Billion ≈ $376.65 Million USD) and total liabilities (CN¥831.08 Million ≈ $121.61 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Baotou Dongbao Bio-Tech Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.74 Billion |
| % of Total Assets | 67.71% |
| Annual Growth Rate | 18.38% |
| 5-Year Change | 7.45% |
| 10-Year Change | 139.71% |
| Growth Volatility | 40.58 |
Net Assets of Baotou Dongbao Bio-Tech Co Ltd (2008–2025)
Net assets of Baotou Dongbao Bio-Tech Co Ltd from 2008 to 2025. This chart illustrates how Baotou Dongbao Bio-Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Baotou Dongbao Bio-Tech Co Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for Baotou Dongbao Bio-Tech Co Ltd (2008–2025)
The table below shows the annual net assets of Baotou Dongbao Bio-Tech Co Ltd from 2008 to 2025. For live market cap and overall valuation, see market value of Baotou Dongbao Bio-Tech Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.72 Billion ≈ $252.16 Million |
-0.93% |
| 2024-12-31 | CN¥1.74 Billion ≈ $254.53 Million |
-8.12% |
| 2023-12-31 | CN¥1.89 Billion ≈ $277.03 Million |
+7.82% |
| 2022-12-31 | CN¥1.76 Billion ≈ $256.94 Million |
+9.49% |
| 2021-12-31 | CN¥1.60 Billion ≈ $234.67 Million |
+60.66% |
| 2020-12-31 | CN¥998.18 Million ≈ $146.07 Million |
+0.64% |
| 2019-12-31 | CN¥991.86 Million ≈ $145.14 Million |
+32.09% |
| 2018-12-31 | CN¥750.88 Million ≈ $109.88 Million |
+2.89% |
| 2017-12-31 | CN¥729.75 Million ≈ $106.79 Million |
+1.52% |
| 2016-12-31 | CN¥718.86 Million ≈ $105.19 Million |
+1.74% |
| 2015-12-31 | CN¥706.55 Million ≈ $103.39 Million |
+107.47% |
| 2014-12-31 | CN¥340.56 Million ≈ $49.83 Million |
-3.11% |
| 2013-12-31 | CN¥351.47 Million ≈ $51.43 Million |
+8.47% |
| 2012-12-31 | CN¥324.03 Million ≈ $47.42 Million |
+9.47% |
| 2011-12-31 | CN¥295.99 Million ≈ $43.31 Million |
+141.74% |
| 2010-12-31 | CN¥122.44 Million ≈ $17.92 Million |
+21.64% |
| 2009-12-31 | CN¥100.65 Million ≈ $14.73 Million |
+2.85% |
| 2008-12-31 | CN¥97.87 Million ≈ $14.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Baotou Dongbao Bio-Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1799.5% over the analyzed period, indicating profitable operations and earnings retention.
Baotou Dongbao Bio-Tech Co Ltd Net Assets Breakdown (December 2025)
Baotou Dongbao Bio-Tech Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥448.91 Million | 26.05% |
| Other Components | CN¥1.27 Billion | 73.95% |
| Total Equity | CN¥1.72 Billion | 100.00% |
Baotou Dongbao Bio-Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Baotou Dongbao Bio-Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tribhovandas Bhimji Zaveri Limited
NSE:TBZ
|
$416.98 Million |
|
Shanghai Sheng Jian Environment Technology Co Ltd
SHG:603324
|
$417.13 Million |
|
Guangzhou Jiacheng
SHG:603535
|
$417.18 Million |
|
Zhejiang Jinlihua Electric Co
SHE:300069
|
$417.23 Million |
|
Chung Hwa Pulp Corp
TW:1905
|
$416.94 Million |
|
Shenzhen Jinxinnong Feed Co Ltd
SHE:002548
|
$416.89 Million |
|
Ellaktor S.A
AT:ELLAKTOR
|
$416.88 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
$416.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Baotou Dongbao Bio-Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,739,542,623 to 1,723,194,833, a change of -16,347,790 (-0.9%).
- Net income of 54,337,307 contributed positively to equity growth.
- Dividend payments of 18,278,322 reduced retained earnings.
- Other factors decreased equity by 52,406,775.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥54.34 Million | +3.15% |
| Dividends Paid | CN¥18.28 Million | -1.06% |
| Other Changes | CN¥-52.41 Million | -3.04% |
| Total Change | CN¥- | -0.94% |
Book Value vs Market Value Analysis
This analysis compares Baotou Dongbao Bio-Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.54x to 1.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.33 | CN¥4.80 | x |
| 2009-12-31 | CN¥0.34 | CN¥4.80 | x |
| 2010-12-31 | CN¥0.41 | CN¥4.80 | x |
| 2011-12-31 | CN¥0.86 | CN¥4.80 | x |
| 2012-12-31 | CN¥0.82 | CN¥4.80 | x |
| 2013-12-31 | CN¥0.89 | CN¥4.80 | x |
| 2014-12-31 | CN¥0.86 | CN¥4.80 | x |
| 2015-12-31 | CN¥1.74 | CN¥4.80 | x |
| 2016-12-31 | CN¥1.56 | CN¥4.80 | x |
| 2017-12-31 | CN¥1.58 | CN¥4.80 | x |
| 2018-12-31 | CN¥1.63 | CN¥4.80 | x |
| 2019-12-31 | CN¥1.96 | CN¥4.80 | x |
| 2020-12-31 | CN¥1.89 | CN¥4.80 | x |
| 2021-12-31 | CN¥2.52 | CN¥4.80 | x |
| 2022-12-31 | CN¥2.58 | CN¥4.80 | x |
| 2023-12-31 | CN¥2.71 | CN¥4.80 | x |
| 2024-12-31 | CN¥2.69 | CN¥4.80 | x |
| 2025-12-31 | CN¥2.90 | CN¥4.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Baotou Dongbao Bio-Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.29%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.48x
- Recent ROE (3.15%) is below the historical average (6.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 12.15% | 9.98% | 0.60x | 2.04x | CN¥2.11 Million |
| 2009 | 11.29% | 7.33% | 0.75x | 2.06x | CN¥1.30 Million |
| 2010 | 17.66% | 11.24% | 0.87x | 1.80x | CN¥9.38 Million |
| 2011 | 8.34% | 11.89% | 0.55x | 1.28x | CN¥-4.93 Million |
| 2012 | 10.92% | 13.84% | 0.53x | 1.50x | CN¥2.98 Million |
| 2013 | 12.13% | 11.16% | 0.74x | 1.48x | CN¥7.49 Million |
| 2014 | 1.44% | 1.95% | 0.47x | 1.56x | CN¥-29.17 Million |
| 2015 | 0.83% | 2.02% | 0.37x | 1.10x | CN¥-64.77 Million |
| 2016 | 2.67% | 6.07% | 0.38x | 1.16x | CN¥-52.66 Million |
| 2017 | 3.07% | 6.29% | 0.37x | 1.33x | CN¥-50.56 Million |
| 2018 | 4.52% | 7.50% | 0.38x | 1.60x | CN¥-41.11 Million |
| 2019 | 3.32% | 6.69% | 0.37x | 1.33x | CN¥-66.27 Million |
| 2020 | 1.86% | 4.11% | 0.32x | 1.43x | CN¥-80.55 Million |
| 2021 | 2.56% | 5.96% | 0.29x | 1.48x | CN¥-105.79 Million |
| 2022 | 7.16% | 11.60% | 0.41x | 1.51x | CN¥-43.41 Million |
| 2023 | 7.23% | 12.30% | 0.36x | 1.65x | CN¥-45.92 Million |
| 2024 | 4.94% | 9.72% | 0.34x | 1.51x | CN¥-87.97 Million |
| 2025 | 3.15% | 7.29% | 0.29x | 1.48x | CN¥-117.98 Million |
Industry Comparison
This section compares Baotou Dongbao Bio-Tech Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Baotou Dongbao Bio-Tech Co Ltd (300239) | CN¥1.74 Billion | 12.15% | 0.48x | $416.96 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private label collagen and unflavored co… Read more